

Incidence of uveitis and uveitis related complications in children with juvenile idiopathic arthritis: results from the Childhood Arthritis Prospective Study

Jeronee Jennycloss¹, Lianne Kearsley-Fleet^{1*}, Kimme L. Hyrich^{1,2}, Coziana Ciurtin³, Saskia-Lawson Tovey^{2,4}, Ameenat Lola Solebo^{5,6,7}, on behalf of the CAPS Investigators group.

1. Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK.
2. NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK.
3. Centre for Adolescent Rheumatology, University College London
4. Centre for Genetics and Genomics Versus Arthritis, The University of Manchester, Manchester, UK
5. Population, Policy and Practice Department, UCL GOS Institute of Child Health, London, UK
6. NIHR Biomedical Research Centre at UCL GOS Institute of Child Health and Great Ormond Street Hospital, London, UK
7. Great Ormond Street Hospital for Children NHS Trust, London, UK

Introduction

Juvenile idiopathic arthritis (JIA) is the most prevalent inflammatory rheumatic disease in children and young people (1, 2). Uveitis, or intraocular inflammation, is the most common extra-articular manifestation of JIA. If JIA-uveitis (JIA-U) is not diagnosed early and thus left untreated, major ocular complications such as cataracts, glaucoma, and blindness can occur (1, 2, 3).

Objectives

To describe the incidence and characteristics of JIA-U among a representative inception cohort of children and young people with JIA enrolled in the Childhood Arthritis Prospective Study (CAPS).

Methods

CAPS, a prospective inception cohort study, recruited children and young people aged <16 years with newly diagnosed inflammatory arthritis across seven UK rheumatology centres between January 2001 (4, 5) and July 2019. Analysis included descriptive statistics of all children recruited from the five centres at which ophthalmic data were available. Detailed ophthalmic data were extracted from clinical records by a paediatric ophthalmologist and comprised visual acuity, date of detection of uveitis, inflammation severity at onset, ophthalmic treatment use, and the presence of and date of detection of ocular structural complications.

Results

Ophthalmic information was available for 1169 (66%) CYP with JIA recruited to CAPS, of whom 158 (14%) were identified as having uveitis. Most patients with JIA-U (N=158) were female (72%), of white ethnicity (76%), had oligoarticular JIA (58%), and had a history of a positive ANA blood test result (69%). The median time from JIA diagnosis to JIA-U diagnosis was 0.9 years [IQR: 0, 2.5] and the median age at JIA-U diagnosis was 5.7yrs [IQR: 3.7, 8.8].

Of the 158 patients reporting uveitis, 94% had anterior uveitis, with 6% having anterior and intermediate uveitis at presentation or over the disease course. Disease presented bilaterally in 107 children (68%), and of the 51 with initially unilateral disease, seven progressed to having bilateral disease. At detection of uveitis, complications (cataract, glaucoma, macular oedema, posterior synechiae, band keratopathy and or visual impairment) were present in 23 children (15%), and 36% of the remaining patients (48/135) went on to develop complications [follow up range 2-10yrs, IQR 5, 10].

Conclusion

This is the first analysis on ophthalmic data collected by the CAPS study and provides an opportunity to examine the characteristics of JIA-U in JIA patients in greater detail. Although 36% of children with uveitis developed sight-threatening complications, most JIA patients with uveitis were diagnosed prior to the onset of complications or did not develop complications.

Bibliography

1. Carvounis PE, Herman DC, Cha S, Burke JP. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. *Graefes Arch Clin Exp Ophthalmol*. 2006;244(3):281-90.
2. Clarke SL, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. *Pediatr Rheumatol Online J*. 2016;14(1):27.

3. Carlsson E, Beresford MW, Ramanan AV, Dick AD, Hedrich CM. Juvenile Idiopathic Arthritis Associated Uveitis. *Children (Basel)*. 2021;8(8).
4. Adib N, Hyrich K, Thornton J, Lunt M, Davidson J, Gardner-Medwin J, et al. Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study. *Rheumatology (Oxford)*. 2008;47(7):991-5.
5. Hyrich KL, Lal SD, Foster HE, Thornton J, Adib N, Baildam E, et al. Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study. *Rheumatology (Oxford)*. 2010;49(1):116-22.

Acknowledgments

We thank all the children and young people and their families who have contributed to CAPS. We thank Versus Arthritis for funding the Special Strategic Grant entitled 'Childhood Arthritis Prospective Study (CAPS)' (UK grant number 20542). We also thank all principal investigators, clinical staff and research coordinators who have made this research possible, as well as members of the research team at the University of Manchester, UK. These include: G Cleary, E Baildam (Alder Hey Children's Hospital, UK), L Wedderburn (Great Ormond Street Hospital, UK), J Davidson (Royal Hospital for Sick Children, Edinburgh and Royal Hospital for Children, Glasgow, UK), A Chieng (Royal Manchester Children's Hospital, UK), F McErlane (Newcastle Hospitals NHS Foundation Trust, UK), H Foster (Royal Victoria Infirmary, UK), C Ciurtin (University College London, UK), Y Ioannou (University College London Hospital, UK) and W Thomson, K Hyrich (University of Manchester). The research team at the University of Manchester are additionally supported by the Centre for Epidemiology Versus Arthritis (UK grant number 21755) and the Centre for Genetics and Genomics Versus Arthritis (UK grant number 21754), and the NIHR Manchester Biomedical Research Centre (NIHR203308) for co-funding of infrastructure support. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.